BBIO241018P30000
- 5.11
- 0.000.00%
BridgeBio Pharma Newsroom
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
BMO Capital Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $37
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
BridgeBio Pharma Analyst Ratings
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
BMO Capital Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $37
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
BridgeBio Pharma Price Target Maintained With a $43.00/Share by HC Wainwright & Co.
BridgeBio Pharma Analyst Ratings
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $42
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $42
Buy Rating Affirmed for BridgeBio Pharma Amid Promising Clinical Trials and Strategic Decisions
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
Piper Sandler Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $46
Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45
BridgeBio Pharma Analyst Ratings
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating